DR
David Risinger Leerink Partners Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Johnson & Johnson
JNJ
$430B
| $178.43 | $153 |
14%
downside
| Market Perform |
13 May ‘25
3 months ago |
|
2
Vertex Pharmaceuticals
VRTX
$102B
| $396.12 | $503 |
27%
upside
| Market Perform |
6 May ‘25
4 months ago |
|
3
Regeneron Pharmaceuticals
REGN
$60.8B
| $573.38 | $834 |
45%
upside
| Outperform |
5 Feb ‘25
7 months ago |
|
4
AbbVie
ABBV
$375B
| $212.56 | $206 |
3%
downside
| Outperform |
22 Nov ‘24
9 months ago |
|
5
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $73 |
55%
upside
| Outperform |
12 Nov ‘24
10 months ago |
|
|
TECX
6
Tectonic Therapeutic, Inc. Common Stock
TECX
$314M
| $16.80 | $69 |
311%
upside
| Outperform |
11 Nov ‘24
10 months ago |
|
7
Tenax Therapeutics
TENX
$27.4M
| $6 | $16 |
167%
upside
| Outperform |
24 Oct ‘24
10 months ago |
|
|
ORKA
8
Oruka Therapeutics, Inc. Common Stock
ORKA
$612M
| $16.35 | $44 |
169%
upside
| Outperform |
17 Sep ‘24
11 months ago |
|
|
ORKA
9
Oruka Therapeutics, Inc. Common Stock
ORKA
$612M
| $16.35 | $44 |
169%
upside
| Outperform |
17 Sep ‘24
11 months ago |
|
10
Vaxcyte
PCVX
$4.29B
| $33.02 | $153 |
363%
upside
| Outperform |
3 Sep ‘24
1 year ago |
|
11
Theravance Biopharma
TBPH
$703M
| $13.95 | $10 |
28%
downside
| Market Perform |
6 Aug ‘24
1 year ago |
|
12
HilleVax
HLVX
$105M
| $2.10 | $2 |
5%
downside
| Market Perform |
9 Jul ‘24
1 year ago |
|
13
AnaptysBio
ANAB
$613M
| $21.90 | $47 |
115%
upside
| Outperform |
16 Apr ‘24
1 year ago |
|
14
Amgen
AMGN
$153B
| $283.64 | $318 |
12%
upside
| Outperform |
11 Oct ‘23
1 year ago |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.11B
| $15.73 | $11 |
30%
downside
| Outperform |
15 Aug ‘23
2 years ago |
|
|
16
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $66 |
40%
upside
| Market Perform |
10 Jul ‘23
2 years ago |
|
17
Eli Lilly
LLY
$652B
| $727.21 | $458 |
37%
downside
| Outperform |
1 May ‘23
2 years ago |
|
|
18
Regeneron Pharmaceuticals
REGN
$60.8B
| $573.38 | $976 |
70%
upside
| Outperform |
27 Mar ‘23
2 years ago |
|
|
CNTA
19
Centessa Pharmaceuticals
CNTA
$2.11B
| $15.73 | $6 |
62%
downside
| Outperform |
17 Mar ‘23
2 years ago |
|
20
Halozyme
HALO
$8.76B
| $74.93 | $42 |
44%
downside
| Market Perform |
16 Mar ‘23
2 years ago |
|
|
21
AbbVie
ABBV
$375B
| $212.56 | $153 |
28%
downside
| Market Perform |
10 Feb ‘23
2 years ago |
|
|
22
Vertex Pharmaceuticals
VRTX
$102B
| $396.12 | $365 |
8%
downside
| Outperform |
8 Feb ‘23
2 years ago |
|
23
Gilead Sciences
GILD
$143B
| $115.05 | $91 |
21%
downside
| Market Perform |
3 Feb ‘23
2 years ago |
|
|
24
Amgen
AMGN
$153B
| $283.64 | $267 |
6%
downside
| Market Perform |
2 Feb ‘23
2 years ago |
|
25
Pfizer
PFE
$141B
| $24.88 | $48 |
93%
upside
| Market Perform |
1 Feb ‘23
2 years ago |
|